TY - JOUR
T1 - Synthetic Pharmacotherapy for Systemic Lupus Erythematosus
T2 - Potential Mechanisms of Action, Efficacy, and Safety
AU - Téllez Arévalo, Angélica María
AU - Quaye, Abraham
AU - Rojas-Rodríguez, Luis Carlos
AU - Poole, Brian D.
AU - Baracaldo-Santamaría, Daniela
AU - Tellez Freitas, Claudia M.
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2023/1
Y1 - 2023/1
N2 - The pharmacological treatment of systemic lupus erythematosus (SLE) aims to decrease disease activity, progression, systemic compromise, and mortality. Among the pharmacological alternatives, there are chemically synthesized drugs whose efficacy has been evaluated, but which have the potential to generate adverse events that may compromise adherence and response to treatment. Therapy selection and monitoring will depend on patient characteristics and the safety profile of each drug. The aim of this review is to provide a comprehensive understanding of the most important synthetic drugs used in the treatment of SLE, including the current treatment options (mycophenolate mofetil, azathioprine, and cyclophosphamide), review their mechanism of action, efficacy, safety, and, most importantly, provide monitoring parameters that should be considered while the patient is receiving the pharmacotherapy.
AB - The pharmacological treatment of systemic lupus erythematosus (SLE) aims to decrease disease activity, progression, systemic compromise, and mortality. Among the pharmacological alternatives, there are chemically synthesized drugs whose efficacy has been evaluated, but which have the potential to generate adverse events that may compromise adherence and response to treatment. Therapy selection and monitoring will depend on patient characteristics and the safety profile of each drug. The aim of this review is to provide a comprehensive understanding of the most important synthetic drugs used in the treatment of SLE, including the current treatment options (mycophenolate mofetil, azathioprine, and cyclophosphamide), review their mechanism of action, efficacy, safety, and, most importantly, provide monitoring parameters that should be considered while the patient is receiving the pharmacotherapy.
KW - antimalarial drug
KW - efficacy
KW - glucocorticoid
KW - immunosuppressant agent
KW - safety
KW - systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85146757791&partnerID=8YFLogxK
U2 - 10.3390/medicina59010056
DO - 10.3390/medicina59010056
M3 - Review article
C2 - 36676680
AN - SCOPUS:85146757791
SN - 1010-660X
VL - 59
JO - Medicina (Lithuania)
JF - Medicina (Lithuania)
IS - 1
M1 - 56
ER -